Introduction
============

Chronic cough is the most common disease in respiratory specialty and community clinics that impairs quality of life (QoL) and increases the economic burden[@B1][@B2]. The common underlying causes associated with chronic cough included asthma syndromes, gastroesophageal reflux disease, upper airway disorders, and various combinations of these diseases[@B3]. Although most patients are treated effectively, cough can persist even after extensive examination or treatment trials in some outpatients. These patients are diagnosed as unexplained chronic cough, idiopathic cough, or refractory chronic cough when there is no identifiable cause[@B4][@B5]. This is always a considerable challenge in clinical practice. Considering the significant medical burden of cough, it is important to establish more effective treatment of patients, especially with chronic cough.

A major hindrance for the development of chronic cough treatment is inadequate understanding of the pathophysiological mechanism of cough. Although it is induced by a variety of stimuli, cough reflex is mediated by the vagal primary afferent nerve that is distributed in the bronchial tree[@B6] and in the extra visceral areas (main bronchus, trachea, and larynx)[@B7]. It is widely accepted that the sensitivity of the cough reflex is increased in chronic cough[@B8][@B9]. Meanwhile, more and more evidences showed that the sensory disorder of the laryngeal branches of vagus nerve is an important pathogenetic mechanism[@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17][@B18]. As pain and cough share the remarkably similar pathways, gabapentin, traditionally used in treatment of neuropathic pain, was recently used as a non-specifc antitussives for chronic idiopathic cough[@B15][@B17][@B19].

Gabapentin has a similar lipophilic structure to the neurotransmitter gamma aminobutyric acid which notoriously performs central action[@B20]. Accordingly, it may also cause central nervous system side effects in the patients taking it. Systematically evaluating the evidence regarding the use of gabapentin medications in the treatment of refractory chronic cough cases may provide views about their efficacy and a better understanding of the studies related to this new therapeutic strategy. Current study is limited by a relatively small sample size, and there was no systematic review of studies regarding gabapentin antitussive therapies. Therefore, our systematic review was conducted to examine the articles concerning the use of gabapentin in the management of chronic cough. We performed the present systematic review to objectively assess the safety and efficacy of gabapentin in chronic cough so as to provide valuable references for clinical medication.

Materials and methods
=====================

1. Data sources and literature search strategy
----------------------------------------------

Data searching were performed using PubMed, Embase, CBM, and Cochrane Library database by two authors independently, from their dates of inception to 1 July 2017. No language and geographical restriction was imposed. We translated non-English publications into English when they were satisfied for inclusion criteria. Search keywords used included: (cough or bronchitis or respiratory tract infections or irritable larynx or pharyngeal diseases or laryngeal diseases or postviral vagal neuropathy or central sensitisation) and (neurontin or gabapentin or gralise or neuromodulator). Unpublished data or data derived only from abstracts were not used. We also searched reference lists of all primary studies and review articles.

2. Inclusion and exclusion criteria
-----------------------------------

We used following inclusion criteria to select studies for the systematic review: (1) adults with chronic cough of unknown etiology at least 8 weeks\' duration, (2) purpose of the use of gabapentin for the treatment of cough, and (3) outcome measures standard should be inclued. Exclusion criteria are as follows: (1) patients younger than 18 years; (2) nonhuman studies; (3) cough due to clear etiology like reflux disease, sinonasal pathology, allergy, pulmonary diseases, angiotensin-converting enzyme inhibitors (ACEIs) and so on; (4) studies with unclear or incomplete information.

3. Outcome measures
-------------------

One or more of the following outcomes should be included: cough severity score, Leicester Cough Questionnaire (LCQ), visual analogue scale (VAS), QoL, cough severity, cough frequency, clinician assessment, urge-to-cough score, and laryngeal dysfunction score.

4. Data extraction and quality assessment
-----------------------------------------

Data were selected and extracted from all of the included studies independently by two authors. Each study was noted by the major information including the reference, country, year of publication, study type, number of participants, patient age, medication regimen, follow-up time, inclusion and exclusion criteria of study, definition of effective treatment, and medication adverse effects. Two reviewers independently evaluated each relevant article and reached agreement for study inclusion. The quality of each trial was assessed by the following trial design features: (1) consecutive status of patients for non randomized controlled trails, (2) type of study outcome, (3) whether study outcome was chosen a priori, and (4) exclusion/inclusion criteria for patient enrollment. Owing to the limited numbers of studies, variability in the quality of researches, and inconsistent reporting of outcomes, no metaanalysis was attempted.

Results
=======

Initial data search identified a total of 206 potentially relevant articles ([Figure 1](#F1){ref-type="fig"}). We removed 30 duplicated articles and excluded 134 after screening the title and abstracts. After reviewing the full-text articles, 34 studies were excluded, mainly because they were reviews and letters without new data or were not satisfactory for the study selection; one study was not included because of the inability to obtain full text[@B21]; we included one article which was a case report about evidence for chronic cough as a sensory vagal neuropathy, owing to it was also a cause of refractory chronic cough[@B18]; a study published in China was also included as it was a relatively complete randomized controlled trials (RCTs)[@B22]; eventually, all together seven papers were selected for further analysis, and a detailed description of these studies is provided ([Table 1](#T1){ref-type="table"}).

Among these two studies were placebo controlled RCTs[@B17][@B22]. The RCTs were placebo controlled, one study participants and researchers were blinded (investigators evaluating the outcome were not blinded)[@B17], and the other did not reported blind method[@B22]. One study was a prospective case series design of consecutive patients[@B14]; two studies were retrospective trails[@B23][@B24], one was a retrospective cohort of consecutive patients, consecutive status in the other retrospective case series was not reported. The rest of the two studies were a case report of two patients consist of one male and one female and a case series of six participants whose consecutive status were not clear[@B6][@B15]. Two studies from same authors were funded by the National Health and Medical Research Council of Australia[@B6][@B17]. The rest of the studies did not describe the financial support. All of the studies included patients with cough for at least 8 weeks ([Table 2](#T2){ref-type="table"}).

The inclusion/exclusion criteria adopted by the investigators included a negative response to empirical treatment trials with proton pump inhibitors, inhaled corticosteroid, oral corticosteroid or nasal corticosteroid treatment[@B6][@B21][@B22]; normal spirometry[@B6][@B21]; smoking[@B17]; modified barium swallow, computed tomography (CT), magnetic resonance imaging (MRI), pH testing[@B14]; gastroesophageal reflux disease and asthma[@B15][@B17][@B23].

In the research of Lee and Woo[@B14], most of the patients had received previous treatment and examination, including the treatment of gastroesophageal reflux disease, modified barium swallow, CT, MRI, and pH monitoring, but it was unclear whether these had been systematically carried out in all patients. In the study by Mintz and Lee[@B15], all patients were treated initially with corticosteroids therapy, not every patient had been evaluated for postnasal drip but did have prior empirical reflux treatment trials and surveys for pulmonary disease in some way. Only an RCT designed by Ryan et al.[@B17] mentioned smoking and ACEI as inclusion criteria.

Different outcome criteria were used to evaluate the clinical therapeutic effect of gabapentin ([Table 3](#T3){ref-type="table"}). The two RCTs used LCQ instruments, VAS and an objective cough monitor to determine cough frequency[@B17][@B22]. Two studies categorized treatment response based on self-reported percent improvement. A study by Lee and Woo[@B14] simply referred to the improvement of clinical symptoms (yes or no), and if the system response was reported by patient\'s self-reported or physician assessment was not clear[@B15]. A cough severity score, which was correlated with the average of the four LCQ scores, was performed by Van de Kerkhove et al.[@B23]. Mintz and Lee[@B15] evaluated the symptom response using clinician reports[@B15]. One RCT by Ryan et al.[@B17] also used capsaicin cough challenge as a measurement to evaluate objective outcome, in which participants\' cough threshold was assessed in response to the chemical tussive capsaicin.

Gabapentin treatment improved symptoms of cough[@B17]. In the two RCTs improvements were seen in cough-specific QoL (LCQ score), cough severity (VAS score), and there was a reduction in cough frequency[@B17][@B22]. The RCT using capsaicin cough challenge showed that capsaicin cough reflex sensitivity did not change significantly with gabapentin treatment[@B17]. One study showed the rate of treatment response was 68% using a binary rating of improvement, compared with 80% in the patients with demonstrable findings of laryngeal neuropathy, while patients without evidences of motor neuropathy had only a 37.5% response rate[@B14]. In the study using clinician assessment response, half of the patients had complete remission and the remaining patients had improved to varying degree in cough[@B15]. One RCT study also evaluated clinical symptom improvement time and found the onset of action of gabapentin was within 4 weeks, and the treatment effect was maintained with maximal dosing during 8 weeks[@B17]. Mintz and Lee[@B15] noted the duration of improvement ranged from 6 months to ongoing. The improvement in cough-specific quality of life was not sustained after discontinuing gabapentin and the LCQ score returned to baseline values[@B17]. A similar trend was also found in cough severity and cough frequency.

Adverse effects may come from gabapentin treatment of chronic cough. Reported side effects included fatigue, dry mouth, drowsiness, and dizziness[@B14][@B15][@B17][@B22][@B23]. Rates of patient-reported side effects in chronic cough patients ranged from 40% to 18% with varying degrees of severity[@B14][@B15][@B17][@B22][@B23]. In two studies, side effects was not reported[@B6][@B24]. One RCT found side effects in 31% of gabapentin group while 10% of patients taking placebo, including confusion, dizziness, nausea, dry mouth, fatigue, headache, blurred vision, and memory loss[@B17]. The other RCT reported adverse events in 40% of gabapentin group vs 23.1% in the placebo group, with similar side effects as Ryan et al.[@B17] reported.

Discussion
==========

This systematic review sought to examine evidence for efficacy and safety of gabapentin in the treatment of chronic cough. We examined the data in the current studies regarding this management strategy. There were considerable distinctions in the quality and type of studies on the treatment of chronic cough, which used gabapentin of interest. Although two RCTs were included, the quality of one study left much to be desired, and owing to the limited numbers of participants, calculation couldn\'t be evaluated comprehensively[@B17][@B22].

The other researches included one non-controlled prospective case series of consecutive participants[@B14], one non-controlled retrospective cohort of consecutive cases[@B23], one retrospective case series[@B24], and two case reports whose consecutive status is unknown[@B6][@B15]. Even though all included researches involved adults with chronic cough of unknown etiology at least 8 weeks\' duration, there were considerable variations between preliminary investigation and previous therapy trails in these studies. Potential heterogeneity may be derived from the exclusion of some particular diagnoses, such as reflux or asthma.

Although different outcome measures were used, it was observed which benefited from gabapentin. Patients experienced improvements were seen in lower LCQ score, VAS score, and a reduction in cough frequency[@B6][@B17][@B22][@B23]. Additionally, over 68% cases obtained some treatment response, and more than 80% had a reduction in varying degrees in symptoms of cough[@B14][@B15][@B22][@B23][@B24]. Nevertheless, there remain some problems, in the case of the optimum dose, treatment duration, time to the best benefit, and symptom reduction rates after therapeutics. Unfortunately, only one RCT reported treatment response, which observed no improvement continuously in cough-specific quality of life after discontinuing gabapentin and the LCQ score returned to baseline values. This may indicate long-term maintenance therapy is suitable for refractory chronic cough, which should be examined by further studies. The neuromodulatory effect of gabapentin on central sensitisation (CS) was noted by one RCT, which reported patients in the treatment group with CS symptoms had noticeable improvements in LCQ score vs those without symptoms of CS[@B17]. Lee and Woo[@B14] reported higher treatment response rate in the patients with demonstrable findings of laryngeal neuropathy than patients without evidences of motor neuropathy. A case report noted that both refractory chronic cough patients with Arnold\'s nerve reflex hypersensitivity were successfully treated with gabapentin[@B6]. Laryngeal irritability, such as laryngospasm and throat clearing, was attributable to cases with additional symptoms[@B14],[@B24]. In addition, Madanick et al.[@B21] reported cases seen in a tertiary care esophageal clinic for esophageal diseases and swallowing for chronic cough that the symptoms improved in most patients with a low-dose gabapentin, no matter the results of reflux testing. Further researches about these subgroups may provide more useful information about the gabapentin treatment on these type-specific patients.

Side effects such as fatigue/drowsiness/dry mouth/lethargy and dizziness generated early and alleviated voluntarily within a short period in the majority of patients, and only a few patients withdraw because of adverse effects[@B17][@B22]. Gabapentin in overdose often generates mild toxicity with clinical presentations without the need for medical treatment[@B25][@B26]. Further investigation into gabapentin long-period security, optimum dose, treatment duration is necessary.

There are variations on the design of study, quality of studies, medical intervention, dosage, and outcomes in included articles. Owing to these inconsistencies, a formal metaanalysis was not conducted. This systematic review showed superior efficacy and a good safety compared with placebo or standard medications in the use of gabapentin for patients with chronic cough, and further more RCTs are needed.
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###### Study type, intervention, sample size, and patient age range of included studies
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  Study                                      Country (year)          Study type                                                                                                                                                                                         No. of patients                                               Patient age (yr)                                            Intervention
  ------------------------------------------ ----------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------
  Van de Kerkhove et al.[@B23]               Belgium (2012)          Retrospective cohort, consecutive patients                                                                                                                                                         10 male, 41 female                                            Mean±SD 47±14                                               Gabapentin 75 mg qd to 1,200 mg daily over 4 wk
  Ryan et al.[@B6]                           Australia (2014)        Case report                                                                                                                                                                                        1 male, 1 female                                              A 61-year-old female                                        1,800 mg/day for 1 mo
  A 69-year-old male                         1,800 mg/day for 3 mo                                                                                                                                                                                                                                                                                                                                
  Bastian and Bastian[@B24]                                          Retrospective case series                                                                                                                                                                          12                                                            Range 23--80                                                Median final dose 1,350 mg
  Ting and Na[@B22]                          China (2016)            Randomized, placebo-controlled patient blinded trial                                                                                                                                               Gabapentin: 11 male, 19 female; placebo: 8 male, 18 female    Range 18--65                                                Gabapentin 300--1,800 mg/day vs. placebo for 12 wk; included a 6-day dose escalation, 8-wk treatment, a 6-day dose reduction
  Gabapentin: mean 50.5 Placebo: mean 52.2                                                                                                                                                                                                                                                                                                                                                        
  Lee and Woo[@B14]                          USA (2005)              Prospective case series, consecutive                                                                                                                                                               9 male, 17 female                                             Mean±SD 51.2±17.0; range 14--80; median 50.5                Gabapentin 100--900 mg daily \>4 wk, nonresponders stop at 4 wk, responders continue dose for 3 mo and then reduction
  Ryan et al.[@B17]                          Australia (2012)        Randomized, double-blinded, placebo-controlled trial; note that patients and research staff were blinded; investigators assessing outcomes were not blinded; block randomization, sex stratified   Gabapentin: 12 male, 20 female; placebo: 10 male, 20 female   Gabapentin: mean±SD 62.7±14.0; placebo: mean±SD 60.9±12.9   Gabapentin 300--1,800 mg/day vs. placebo for 84 days; included a 6-day dose escalation, 8-wk treatment, a 6-day dose reduction
  Mintz and Lee[@B15]                        Canada (2006)           Case series, consecutive status unknown                                                                                                                                                            6 female                                                      Mean 59; range 34--77                                       Gabapentin 100 mg bid to 1,600 mg daily dose

qd: once daily; bid: twice a day.

###### Diseases excluded, follow-up, and cough duration of included studies
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  Study                                                                  Inclusion/exclusion criteria                                                                                                                                                                                                                                                                                                                      Follow-up                                                                                            Duration of cough
  ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -----------------------------------------------------
  Van de Kerkhove et al.[@B23]                                           All patients failed empirical treatment trials with proton pump inhibitors (≥6 wk of omeprazole 40 mg twice daily), nasal decongestants, (≥6-wk fluticasone 100 μg twice daily or equivalent) and inhaled steroids (≥6-wk fluticasone 250 μg twice daily or equivalent)                                                                           Mean follow-up, unknown                                                                              Median duration 48 mo
  Ryan et al.[@B6]                                                       Normal spirometry and a negative response to previously trialled proton pump inhibitor, inhaled corticosteroid treatment, oral corticosteroids or nasal steroid treatment.                                                                                                                                                                        1 mo                                                                                                 30 mo
  3 mo                                                                   96 mo                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Bastian and Bastian[@B24]                                              Gastroesophageal reﬂux disease, asthma, and allergy with no reduction of cough were included                                                                                                                                                                                                                                                      ≥6 mo                                                                                                Median 60 mo
  Ting and Na[@B22]                                                      Normal spirometry and a negative response to previously trialled proton pump inhibitor, corticosteroid treatment, antitussive, SABA                                                                                                                                                                                                               NR                                                                                                   Gabapentin: median 32 mo; range 13--96 mo
  Structural disease were exclued                                        Placebo: median 39 mo; range 11--90 mo                                                                                                                                                                                                                                                                                                                                                                                                                 
  Lee and Woo[@B14]                                                      Prior workup included (not systematic or uniform across all patients):                                                                                                                                                                                                                                                                            Mean follow-up, unknown                                                                              Median 7.5 mo; range 1.5--240 mo
   Modified barium swallow                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
   CT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   MRI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
   pH testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Ryan et al.[@B17]                                                      Smoking                                                                                                                                                                                                                                                                                                                                           Treatment visits after 4 wk and 8 wk of treatment; additional assessment 4 wk after drug cessation   Gabapentin: median 36 mo; range 18--150 mo
   Pulmonary disease or infection (including asthma, productive cough)   Placebo: median 48 mo; range 18--156 mo                                                                                                                                                                                                                                                                                                                                                                                                                
   Reflux                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
   Postnasal drip                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
   ACEI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   Pregnant/breastfeeding                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
   Impaired liver function                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Mintz and Lee[@B15]                                                    Not systematic or uniform across patients: gastroesophageal reflux disease, asthma, postnasal drip exclusion mentioned in the abstract; article mentions privious workup, including bronchoscopy, upper gastrointestinal series, bronchoalveolar lavage, methacholine challenge test, serology (ANA, IgG, pertussis IgA, α-1-antitrypsin, etc.)   12 mo                                                                                                Median 7.5 mo; range 1.5--240 mo; mean±SD 31.4±57.4

SABA: short-acting β2 agonist; NR: not reported in study; CT: computed tomography; MRI: magnetic resonance imaging; ACEI: angiotensin-converting enzyme inhibitors; ANA: anti-nuclear antibody.

###### Outcome measure, results, and side effects of included studies

![](trd-81-167-i003)

  Study                                                                                                                                                                       Outcome                                                                Result                                                                                                                                                                                                                   Side effect
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Van de Kerkhove et al.[@B23]                                                                                                                                                Cough Severity score                                                   Eight subjects discontinued during treatment due to adverse effects; eight subject did not start the treatment because of a fear of side-effects; 35 patients a mean reduction in cough severity score of 2.8 was seen   Fatigue (n=5) dizziness (n=3) 19%, nausea 9%
  Ryan et al.[@B6]                                                                                                                                                            Leicester Cough Questionnaire (LCQ)                                    Improved                                                                                                                                                                                                                 NR
  Quality of life                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Cough severity                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Bastian and Bastian[@B24]                                                                                                                                                   Symptom response (patient report)                                      10 Responded                                                                                                                                                                                                             NR
  69% Reduction of symptoms                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Ting and Na[@B22]                                                                                                                                                           LCQ                                                                    54 Patients improved LCQ and VAS scores, decreased cough times                                                                                                                                                           Adverse events reported in 40% of gabapentin group: two patients withdrewed because of side effect; adverse events reported in 23.1% of placebo group
  VAS                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Cough frequency                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Lee and Woo[@B14]                                                                                                                                                           Symptom response (unclear if clinician or patient report), yes or no   69% Improved; variable responses depending on presence of neuropathy upon laryngeal electromyography                                                                                                                     Dizziness or somnolence in 18% of all enrolled patients
  Ryan et al.[@B17]                                                                                                                                                           Primary end point: cough specific quality of life                      Improved cough-specific QoL scores, cough severity, cough frequency compared with placebo; no effect on capsaicin cough reflex sensitivity                                                                               Gabapentin group: 31% such as fatigue, confusion, dizziness, dry mouth, and/or nausea; headache, blurred vision, and memory loss reported in only one patient each
  Secondary end points: cough severity, capsaicin cough reflux sensitivity, cough frequency using objective cough monitor, urge-to-cough score, laryngeal dysfunction score   Effects not sustained after treatment cessation                        Placebo group: 10%                                                                                                                                                                                                       
  Mintz and Lee[@B15]                                                                                                                                                         Clinician assessment                                                   Three of six complete resolution, one 10% to 15% improved, one probably improved, one decreased frequency and intensity of cough                                                                                         Fatigue in 17%, drowsiness in 17%

NR: not reported in study; VAS: visual analogue scale; QoL: quality of life.
